 |
SALT LAKE CITY,
June
2
,
2010—BSD Medical Corporation (NASDAQ:BSDM) today reported impressive results
from a clinical study on the use of hyperthermia, delivered using the BSD-2000
Hyperthermia System, to treat pancreatic cancer.
Dr. S. Maluta, University Hospital of Verona, Italy,
reported the results of a randomized Phase II study of 74 patients with
advanced pancreatic cancer: “Hyperthermia combined with radiochemotherapy in
unresectable locally or recurrent advanced pancreatic cancer, a Phase II
perspective study.”
Dr. Maluta reported that the
recurrent and metastatic pancreatic patients who were treated with hyperthermia
combined with radiochemotherapy had a median survival of 14 months, as compared
to a median survival of only 5 months for those treated with radiochemotherapy
alone (n=20). The one year survival was increased by 3 months for all patients
who were treated with hyperthermia, as compared to patients who did not receive
hyperthermia treatment (n=54). The treatment was well tolerated with no
increase in toxicity from the addition of hyperthermia.
Dr Maluta reported that these results
support initiation of a Phase III study. The results were presented at the
annual European Society of Hyperthermic Oncology (ESHO) Meeting, which was held
in Rotterdam, The Netherlands, on May 19 to 21, 2010.
Rolf Issels MD
PhD, the President of ESHO, supported initiation of a randomized Phase III
study on hyperthermia treatment of pancreatic cancer and stated in his keynote
lecture, “In a time of evidence based oncology loco-regional hyperthermia has
proven its value and deserves a greater focus and exploration”.
Pancreatic
cancer i
s one of the
deadliest and hardest to treat
cancers and is the fourth leading cause of cancer-related death in
the United States.
More than 30,000
people in the US and 60,000 in Europe are annually diagnosed with pancreatic
cancer.
The median survival period from the time of diagnosis
until death is 3.5 to 6 months, depending on treatment,
and less than 5 percent survive to five years.
Advanced
pancreatic cancer
patients currently have
few treatment options.
About the
European Society for Hyperthermic Oncology
ESHO was organized to promote research relating to the use of hyperthermia in
cancer therapy and to facilitate the exchange of information among multiple
disciplines regarding the study of heat in the treatment of cancer.
About BSD Medical
Corporation
BSD
Medical Corporation develops, manufactures, markets and services systems to
treat cancer and benign diseases using heat therapy delivered using focused
radio frequency (RF) and microwave energy.
BSD’s product lines include both hyperthermia and ablation
treatment systems.
BSD’s
hyperthermia cancer treatment systems, which have been in use for several years
in the United States, Europe and Asia, are used to treat certain tumors with
heat (hyperthermia) while increasing the effectiveness of other therapies such
as radiation therapy.
BSD’s
microwave ablation system, which the Company will introduce to the market this
year, has been developed as a stand-alone therapy to employ precision-guided microwave
energy to ablate (destroy) soft tissue.
The Company has extensive intellectual property, multiple products in
the market and well established distribution in the United States, Europe and
Asia.
Certain of the Company’s
products have received regulatory approvals in the United States, Europe and
China.
The BSD-2000 is restricted
to investigational use in the US.
For
further information visit BSD Medical's website at
www.BSDMedical.com
.
###
Statements
contained in this press release that are not historical facts are
forward-looking statements, as defined in the Private Securities Litigation
Reform Act of 1995. All forward-looking statements are subject to risks and
uncertainties detailed in the Company's filings with the Securities and
Exchange Commission. These forward-looking statements speak only as of the date
on which such statements are made, and the Company undertakes no obligation to
update such statements to reflect events or circumstances arising after such
date.
|
